• Clarity signs Supply Agreement with Nusano for copper-67 isotope supply
• Nusano's facility in Utah expected to begin operations in late 2025 and supply copper-67 from mid-2026
• Nusano's accelerator-based technologies well suited for high-volume mass production of copper-67

Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company, has announced the signing of a Supply Agreement for copper-67 with Nusano, Inc. Nusano's state-of-the-art facility in West Valley City, Utah is expected to begin operations in late 2025 and supply copper-67 isotope from mid-2026. Nusano's proprietary accelerator-based technologies are well suited for high-volume mass production of copper-67, which is crucial for Clarity's clinical trials and commercial use of its lead product 67Cu-SAR-bisPSMA for the treatment of prostate cancer. The copper-67 supply from Nusano further expands Clarity's growing network of US-based suppliers, including NorthStar Medical Radioisotopes and Idaho State University Idaho Accelerator Center. Clarity's Executive Chairperson, Dr Alan Taylor, commented that the reliable, abundant, sustainable and cost-effective supply of copper-67 is essential for the clinical development and potential commercialization of their theranostic program. Nusano's CEO, Chris Lowe, expressed excitement to deepen the relationship with Clarity and support their copper-67 program.

Clarity is in a unique position with their copper-67 program, being the only radiopharmaceutical company with ongoing clinical trials utilizing this important isotope. The company looks forward to progressing their theranostic program, pending final study findings, and working with Nusano to have numerous pathways to producing large quantities of copper-67 to enable their clinical and commercial efforts.